Abbott Consent Decree Costs Escalate With Failed FDA QSR Inspection
This article was originally published in The Gray Sheet
Executive Summary
Costs related to Abbott's FDA consent decree could approach $1 bil. in lost revenue alone following a failed follow-up inspection of the company's Lake County, Illinois diagnostic manufacturing operations
You may also be interested in...
Approvals For Long-Pending PMAs Drive Up Average Approval Times In 2004
The average elapsed time between submission and FDA approval for original PMAs increased from 350 days in 2003 to 504 in 2004
Approvals For Long-Pending PMAs Drive Up Average Approval Times In 2004
The average elapsed time between submission and FDA approval for original PMAs increased from 350 days in 2003 to 504 in 2004
Abbott’s Lake County Plant Gets FDA Nod; Prism Squares Up For U.S. Debut
Abbott Labs will begin U.S. commercialization of its Prism, Architect and AxSYM full diagnostic assay menus over the next 12 months, following FDA's decision to end a four-year prohibition of product sales